Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Lynda A. Szczech"'
Autor:
Khalil G. Saikali, Tyson Lee, Lynda A. Szczech, Ming Zhong, Dustin J. Little, John Houghton, Mark T. Houser, Robert Leong, Robert Provenzano, Lars Frison, Thomas B. Neff
Publikováno v:
Clin J Am Soc Nephrol
Background and objectives We evaluated the efficacy and cardiovascular safety of roxadustat versus placebo by analyzing data pooled from three phase 3 studies of roxadustat in patients with non–dialysis-dependent CKD and CKD-related anemia. Design,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ec68d1a745ebbdce559e0f32e41590d
https://doi.org/10.2215/cjn.16191020
https://doi.org/10.2215/cjn.16191020
Autor:
Willis Chou, Sung Gyun Kim, Lynda A. Szczech, Andres A. Cadena, Daniel W. Coyne, Anatole Besarab, Robert Leong, Moustafa A. Moustafa, Tyson Lee, Simon D. Roger, Meraf Eyassu, Kin-Hung Peony Yu, Tak Mao Chan, Sug Kyun Shin, Charles Bradley, Khalil G. Saikali
Publikováno v:
Kidney International Reports
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and tolerability of roxadustat in patients with chronic kidney disease (CKD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::471632625ebd6cf524b6d0552d64463f
https://doi.org/10.1016/j.ekir.2020.11.034
https://doi.org/10.1016/j.ekir.2020.11.034
Autor:
Charles Bradley, Lona Poole, Robert Leong, Anatole Besarab, Liubov Eremeeva, Lynda A. Szczech, Meraf Eyassu, Thomas B. Neff, Kin-Hung Peony Yu, Evgeny Shutov, Cameron Liu, Robert Provenzano, Gopal Saha, Svitlana Korneyeva
Publikováno v:
Nephrology Dialysis Transplantation. 36:1717-1730
Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods HIMALAYAS was a Phase 3, open-label, epoetin alfa-controlled trial. Elig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb75680793426ec819f4ff73c2ac112
https://doi.org/10.1093/ndt/gfab051
https://doi.org/10.1093/ndt/gfab051
Autor:
Carol A. Pollock, Aisha Chow, Gail Walkenshaw, David Gervasi, Lynda A. Szczech, Simon D. Roger
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in China and Japan for the treatment of anemia in patients with chronic kidney disease (CKD). In Phase 3 clinical studies, roxadustat wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9dd1a09a26f72eff0bb60383acb2c8a
https://doi.org/10.1093/ndt/gfab118.001
https://doi.org/10.1093/ndt/gfab118.001
Autor:
Robert Leong, Dustin J. Little, P. Pergola, S. Tham, Steven Fishbane, Chaim Charytan, Lynda A. Szczech
Publikováno v:
Kidney International Reports, Vol 6, Iss 4, Pp S120-S121 (2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45dbe3012368bfd5d384946bf6e1b6dd
http://www.sciencedirect.com/science/article/pii/S2468024921004447
http://www.sciencedirect.com/science/article/pii/S2468024921004447
Autor:
Lynda A Szczech, Rebecca C Stewart, Hsu-Lin Su, Richard J DeLoskey, Brad C Astor, Chester H Fox, Peter A McCullough, Joseph A Vassalotti
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e110535 (2014)
This US, multicenter, observational study assessed the CKD prevalence in adult patients with type-2 diabetes mellitus (T2DM) and characterized the proportion of detected and undiagnosed CKD in the primary care setting using the following: a clinician
Externí odkaz:
https://doaj.org/article/b5d495ef711c433bbf2a61e0faccbfeb
Autor:
Kin-Hung Peony Yu, Robert Provenzano, Lars Frison, John Houghton, Lynda A. Szczech, Dustin J. Little, Ming Zhong, Robert Leong, Steven Fishbane, Tyson Lee, Thomas B. Neff, Mark T. Houser, Khalil G. Saikali
Publikováno v:
Kidney International Reports
Introduction Erythropoiesis-stimulating agents are associated with increased cardiovascular risk when higher doses are used toward higher hematocrit targets. Patients new to dialysis are at higher risk for morbidity and mortality. Systematic evaluati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a54003ce8bf2b2602f2f04a1f084ab3
https://pubmed.ncbi.nlm.nih.gov/35257087
https://pubmed.ncbi.nlm.nih.gov/35257087
Autor:
Xueqing Yu, Cameron Liu, Qiang He, Jiaqi Qian, Nan Chen, Hongli Lin, Anatole Besarab, Frank H. Valone, Xuemei Li, Li Zuo, Chuanming Hao, Kin-Hung Peony Yu, Lynda A. Szczech, Jianghua Chen, Ping Fu, Dalvin Ni, Gengru Jiang, Changlin Mei, Stefan Hemmerich, Xinzhou Zhang, Thomas B. Neff
Publikováno v:
Nephrology Dialysis Transplantation
Background FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5c7c4a602c0f7df356acc0ca3eb03fd
https://doi.org/10.1093/ndt/gfx011
https://doi.org/10.1093/ndt/gfx011
Autor:
Li Zuo, Laimin Luo, Cai-Li Wang, Bi-Cheng Liu, Zhihong Liu, Thomas B. Neff, Xinling Liang, Zhengrong Liu, Chuanming Hao, Li Hao, Hongli Lin, Robert Leong, Jianqin Wang, Cameron Liu, Nan Chen, Changying Xing, Guang-Yan Cai, Xuemei Li, Ming-Hui Zhao, Kin-Hung Peony Yu, Lynda A. Szczech, Chunrong Wang, Gengru Jiang
Publikováno v:
The New England journal of medicine. 381(11)
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9176016e7a91322880cd6fa14fb6cd61
https://pubmed.ncbi.nlm.nih.gov/32609998
https://pubmed.ncbi.nlm.nih.gov/32609998
Autor:
Zhengrong Liu, Bi-Cheng Liu, Nan Chen, Kin-Hung Peony Yu, Chunrong Wang, Xinling Liang, Yunhua Liao, Laimin Luo, Thomas B. Neff, Xiaomei Peng, Hongli Lin, Li Zuo, Cameron Liu, Ye Tao, Aiping Yin, Changying Xing, Li Hao, Robert Leong, Jianghua Chen, Chuanming Hao, Lynda A. Szczech
Publikováno v:
The New England journal of medicine. 381(11)
Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased level
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87a3086fbd9e88cb57ba066ff92a0db
https://pubmed.ncbi.nlm.nih.gov/32610000
https://pubmed.ncbi.nlm.nih.gov/32610000